

DRA contract ends & New advisory board member.

Panion Animal Health AB's Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.

Niels-Erik Manniche's contract expires on the 31st of March 2018, and he is available for the company in this period, if needed. Niels-Erik has been involved since the establishment of Panion and wishes us the best of luck for the future.

Anja Holm, CEO, takes over his responsibilities until the board has taken a new organizational decision.

Panion's advisory board has been expanded with Dr. Curtis W. Dewey from Cornell University, New York.

Dr. Curtis Dewey, DVM, MS, is a Diplomate of the American College of Veterinary Internal Medicine (Neurology), a Diplomate of the American College of Veterinary Surgeons, and an Associate Professor at the Section of Neurology/Neurosurgery in the veterinary faculty of Cornell University, Ithaca, New York, U.S.A.

Dr. Dewey's main research interests include seizure management, congenital disorders of the central nervous system, and complementary therapies for neurologic disease. Species focus is on dogs and cats.

Advisory board membership is a voluntary, independent, and non-remunerated position.

For further information, please contact:

Anja E. H. Holm, CEO | +45-22 94 66 00
anja.holm@panion-animalhealth.com

Developing animal health – In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget.

Panion Animal Health AB

Frykholmogatan 11, 281 31 Hässleholm, Sweden
info@panion-animalhealth.com

[linkedin.com/company/panion-animalhealth](https://www.linkedin.com/company/panion-animalhealth) 
twitter.com/panionanihealth 
panion-animalhealth.com/newsletter 
panion-animalhealth.com 